Format

Send to

Choose Destination
Oncogene. 2019 Feb 12. doi: 10.1038/s41388-019-0737-2. [Epub ahead of print]

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.

Author information

1
Department of Experimental Medicine, University of Genoa, Genoa, Italy.
2
Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
3
Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy.
4
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
5
Department of Experimental Medicine, University of Genoa, Genoa, Italy. paolo.malatesta@unige.it.
6
Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy. paolo.malatesta@unige.it.

Abstract

Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.

PMID:
30755732
DOI:
10.1038/s41388-019-0737-2

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center